Protalix BioTherapeutics Files 8-K
Ticker: PLX · Form: 8-K · Filed: Nov 3, 2025 · CIK: 1006281
| Field | Detail |
|---|---|
| Company | Protalix Biotherapeutics, Inc. (PLX) |
| Form Type | 8-K |
| Filed Date | Nov 3, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, sec-filing
TL;DR
Protalix BioTherapeutics filed an 8-K on Nov 3, 2025, but details are sparse in this excerpt.
AI Summary
Protalix BioTherapeutics, Inc. filed an 8-K on November 3, 2025, reporting on other events and financial statements. The filing does not contain specific financial figures or details about the 'other events' in the provided text.
Why It Matters
This 8-K filing indicates Protalix BioTherapeutics, Inc. has made a regulatory submission, but the specific details of the events or financial statements are not elaborated in the provided excerpt.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing header and does not contain information that poses an immediate risk.
Key Players & Entities
- Protalix BioTherapeutics, Inc. (company) — Registrant
- November 3, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-33357 (identifier) — Commission File Number
- 65-0643773 (identifier) — IRS Employer Identification No.
- 2 University Plaza (address) — Business Address
FAQ
What is the primary purpose of this 8-K filing?
The 8-K filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on 'Other Events' and 'Financial Statements and Exhibits'.
When was this 8-K filing submitted?
The filing was submitted on November 3, 2025.
What is the company's full legal name and state of incorporation?
The company's full legal name is Protalix BioTherapeutics, Inc., and it is incorporated in Delaware.
What is the Commission File Number for Protalix BioTherapeutics, Inc.?
The Commission File Number is 001-33357.
What is the business address of Protalix BioTherapeutics, Inc.?
The business address is 2 University Plaza, Suite 100, Hackensack, NJ 07601.
Filing Stats: 490 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2025-11-03 16:44:01
Key Financial Figures
- $0.001 — ange on which registered Common stock, $0.001 par value PLX NYSE American Indic
Filing Documents
- plx-20251103x8k.htm (8-K) — 39KB
- plx-20251103xex99d1.htm (EX-99.1) — 29KB
- plx-20251103xex99d1001.jpg (GRAPHIC) — 10KB
- plx-20251103xex99d1002.jpg (GRAPHIC) — 5KB
- 0001104659-25-105594.txt ( ) — 208KB
- plx-20251103.xsd (EX-101.SCH) — 3KB
- plx-20251103_lab.xml (EX-101.LAB) — 16KB
- plx-20251103_pre.xml (EX-101.PRE) — 11KB
- plx-20251103x8k_htm.xml (XML) — 5KB
01
Item 8.01 Other Events On November 3, 2025, Protalix BioTherapeutics, Inc., a Delaware corporation (the "Company"), issued a press release, together with its development and commercialization partner, Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., announcing that they have requested a re-examination of the recent negative opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding the proposed dosing regimen of 2 mg/kg body weight infused every 4 weeks (E4W) for Elfabrio (pegunigalsidase alfa). A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release dated November 3, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 3, 2025 PROTALIX BIOTHERAPEUTICS, INC. By: /s/ Dror Bashan Name: Dror Bashan Title: President and Chief Executive Officer